glp·helper
glphelper.com/ozempic/utah/salt-lake-city
GLP-1 receptor agonistFDA-approved December 2017Rx · Subcutaneous injection · Once weekly

Ozempic® providers &
prescriptions in Salt Lake City, UT

Dr. Fahad Akhtar, M.D.
Medically reviewed by Dr. Fahad Akhtar, M.D.
Physician at g1v.me, an affiliated practice

Ozempic is FDA-approved for type 2 diabetes, not for weight management.[1] The semaglutide approved for chronic weight management is Wegovy in Salt Lake City.

Physicians near Salt Lake City, UT from the federal NPI registry. Ask each office whether it prescribes Ozempic.[9]

city providers
36
as of today

Same molecule (semaglutide): Wegovy in Salt Lake City, Semaglutide in Salt Lake City

Other GLP-1 medicines: Tirzepatide in Salt Lake City, Mounjaro in Salt Lake City, Zepbound in Salt Lake City

§ 02Provider directory: Utah
36 of 36 shown

Find an Ozempic provider in Salt Lake City.

Every entry comes from the federal NPI registry. Ask each office what it prescribes. We do not accept payment for placement.

Filter →
Type
Provider
City
Insurance / phone
Ozempic by Utah town, physicians per town
§ 03Getting Ozempic in Salt Lake City
36 providers · Salt Lake City, UT

How to get Ozempic in Salt Lake City.

36 GLP-1 prescribers and 7 local resource types are on record for Salt Lake City, plus 2 nearby towns in the directory.

Physicians in Salt Lake City
36 physicians
36 physicians from the federal NPI registry in Salt Lake City, most listed as Internal Medicine, Endocrinology, Diabetes & Metabolism (14), Family Medicine (13) and Internal Medicine (8). A licensed clinician who evaluates you decides whether an FDA-approved GLP-1 fits. Telehealth rules vary by state. The nearest towns on record are West Valley City (26 providers) and Provo (27 providers).
Around the prescription in Salt Lake City
7 listed nearby
6 dietitians, 6 nutritionists, 6 gyms, 6 fitness clubs, 6 trainers, 6 physiotherapists and 6 places to move are on record near Salt Lake City.
Medicaid (weight loss)
Covered
As of April 2026, Utah Medicaid covers GLP-1s for weight loss, usually with prior authorization and BMI criteria, on top of the standard diabetes coverage. Employer and private plans vary; coverage is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Utah’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

An injectable medication for adults with type 2 diabetes, and, by indirect effect, for body weight.

Ozempic is the brand name for semaglutide, a once-weekly subcutaneous injection in the GLP-1 receptor agonist class. It mimics a gut hormone that signals satiety to the brain and slows gastric emptying. In the trials on its FDA label, the 1 mg dose lowered HbA1c by 1.4 to 1.9 percentage points and body weight by a mean of 4.7 to 6.0 kg over 30 to 56 weeks. The 2 mg dose lowered body weight by a mean of 6.4 kg over 40 weeks.[2][3]

It is FDA-approved for glycemic control in adults with type 2 diabetes mellitus and for reducing the risk of major cardiovascular events in adults with T2D and established cardiovascular disease. The same molecule, marketed by the same manufacturer as Wegovy, is the FDA-approved formulation for chronic weight management.[1]

For the receptor story in plain English, read how does ozempic work.

Rapid weight loss can change the midface. The mechanism people call ozempic face is in the research notes.

Bar chart of Ozempic dose strengths on the FDA label: 0.25 mg, 0.5 mg, 1 mg, 2 mg
Ozempic comes in 4 strengths: 0.25 mg, 0.5 mg, 1 mg, 2 mg. The chart shows what the label lists. A prescriber sets the dose.[1]
At a glanceNDC 0169-4132
Active ingredient
semaglutide
Drug class
GLP-1 receptor agonist
Manufacturer
Novo Nordisk
FDA approved
December 2017
Approved use
Type 2 diabetes mellitus (adults)
Off-label use
Not FDA-approved for weight management. Wegovy is the semaglutide approved for it
Administration
Subcutaneous injection · Once weekly
Available doses
0.25 mg · 0.5 mg · 1 mg · 2 mg
Half-life
≈ 7 days
Pregnancy
Discontinue ≥ 2 months before planned pregnancy

Community health · CDC

Weight & metabolic health in Utah

Diagnosed diabetes reaches 8.1% of adults in Utah.

of Utah adults have obesity
31%
diagnosed diabetes
8.1%

Age-adjusted estimates for Utah, community figures, not individual risk. CDC BRFSS 2024.

Estimate your weight lossGLP-1s and fertility
§ 05Support around Ozempic in Salt Lake City
6 dietitians

The prescription is one part. Here is the rest, in Salt Lake City.

Trials of semaglutide paired the drug with diet counseling and regular activity. Every name below is a real listing near Salt Lake City, UT, ordered as the registry lists them, never by who pays us.

Registered dietitians

A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.

Sydney Abbott
RD
Registered dietitian
650 S Komas Dr
Call 801-581-5585NPI 1528444569
Andrea Addley
RD
Registered dietitian
1174 E Graystone Way Ste 1A
Call 801-664-2182NPI 1013255066
Carly Alba
RD
Registered dietitian
5121 S Cottonwood St
Call 801-507-7000NPI 1033856539
Adrienne Aldous, Ph.D. R.D
RD
Registered dietitian
3762 Eastcliff Cir
Call 801-278-9571NPI 1982905386
Crystal Alvarez
RD
Registered dietitian
500 Foothill Dr Rm 1A03
Call 801-582-1565NPI 1639095912
Madison Anderson, RDN
RD
Registered dietitian
8Th Ave C Street 8Th
Call 801-408-1100NPI 1245931393

Nutritionists

A nutritionist helps you get enough protein and fiber while the medication cuts your appetite. Call to ask what they cover.

Elise Christensen, MS
NUTRITIONIST
Nutritionist · Education
170 N 1100 E
Call 801-855-3300NPI 1255549531
Mcauley Duda, FDN, CNP, Nutritioni
NUTRITIONIST
Nutritionist · Education
1224 S Navajo St
Call 413-519-2374NPI 1851231765
Felicia Ferry
NUTRITIONIST
Nutritionist · Education
344 E 100 S Ste 301
Call 801-428-4257NPI 1588248405
Heather Khader
NUTRITIONIST
Nutritionist · Education
1200 E 3900 S
Call 801-268-7860NPI 1457370314
Amanda Luekenga
NUTRITIONIST
Nutritionist · Education
1200 E 3900 S
Call 801-268-7860NPI 1396765822
Chelsie Moore, CNS
NUTRITIONIST
Nutritionist
823 S 900 E
Call 530-307-9789NPI 1861963456
§ 06Clinical evidence
N = 8,416 across SUSTAIN 1 to 7

What the trials actually showed.

We summarize results from the SUSTAIN program, the seven Phase III randomized trials Novo Nordisk submitted to the FDA, and the SUSTAIN-6 cardiovascular outcomes trial. Numbers below are means at the 30-week endpoint, 1 mg weekly dose.

SUSTAIN 1 through 7 compared semaglutide against placebo, sitagliptin, exenatide ER, insulin glargine, and dulaglutide. Semaglutide produced superior HbA1c and body-weight reductions in every active comparator trial.[3]
SUSTAIN endpoint table1 mg / 30 wk
HbA1c reduction
−1.4 to −1.9%
mean, 1 mg dose, 30 to 56 wk[1]
Weight change
−4.7 to −6.0 kg
mean, 1 mg dose, 30 to 56 wk[1]
Major adverse cardiac events
−26%
HR 0.74 vs. placebo[2]
Patients reaching HbA1c <7%
72%
1 mg dose, 30 wk[3]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average Ozempic weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most Ozempic side effects are stomach and gut effects.

In Ozempic's diabetes trials at 0.5 mg and 1 mg, the most common side effects were nausea (15.8 to 20.3%), diarrhea (8.5 to 8.8%), and vomiting (5 to 9.2%). Most reports came during dose escalation.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[1]

Boxed warning. Contraindicated in personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
15.8 to 20.3%
mild
Most common. Most reports came during dose escalation
Diarrhea
8.5 to 8.8%
mild
More frequent during dose escalation
Vomiting
5 to 9.2%
mild
Reduced by slower titration
Constipation
3.1 to 5%
mild
Abdominal pain
5.7 to 7.3%
moderate
Pancreatitis
<0.3%
serious
Discontinue if confirmed; black-box adjacent
Gallbladder disease
1.5%
serious
Cholelithiasis risk elevated with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated in MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

What Ozempic costs, by how you pay.

The price you pay depends on your insurance plan, your diagnosis, and how you buy. Manufacturer self-pay programs cost far less than pharmacy retail. Here are the ranges.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk self-pay and savings pages.

Self-pay and savings card prices checked . Retail averages from May 2026.

Ozempic monthly cost by how you pay
Pharmacy retail (no insurance)$1,476per monthBrand-name retail average, May 2026[6]
NovoCare self-pay, pen$349 to $499per month0.25, 0.5, and 1 mg $349. 2 mg $499
Commercial insurance (covered)$25 to $250per month copayVaries by PBM; T2D indication usually covered
Weight managementNot approvedOzempic is not FDA-approved for weight management. Wegovy is.
Medicare Part D$0 to $100per monthT2D covered; weight loss not covered by law[5]
Manufacturer savings cardas low as $25per monthCommercial only; eligibility limits apply
Find Ozempic providers in Salt Lake City

Physicians from the federal NPI registry. Ask each office whether it prescribes Ozempic.

Ozempic in other states

Physicians from the federal NPI registry in the states we cover. Ask each office whether it prescribes Ozempic.

Related GLP-1 research
§ 09Frequently asked: Ozempic in Utah

The questions people ask before they book.

Answers reviewed by the glp·helper Medical Team. Citations link to primary sources, never marketing copy.

Yes. Ozempic is a prescription-only medicine, marked Rx only on its label. A licensed prescriber (MD, DO, NP, or PA) must evaluate you before issuing a prescription.[1]